Charles River Laboratories International (CRL) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Charles River Laboratories International (CRL) has outperformed MaxCyte (MXCT) over the past year, gaining 76.5% versus a loss of 32.9%. Over five years, CRL leads with a -25.6% price change compared with -90.6% for MXCT. Charles River Laboratories International is the larger company by market cap ($13.97 billion vs $101.7 million), about 137.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRL | MXCT |
|---|---|---|
| Share price | $289.99 | $0.985 |
| Market cap | $13.97B | $101.66M |
| 1-day change | -3.43% | -5.29% |
| YTD return | +50.54% | -32.90% |
| 1-year return | +76.54% | -32.90% |
| 5-year return | -25.58% | -90.57% |
| Forward P/E | 22.70 | — |
| EPS (TTM) | $-4.80 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.02B | — |
| Revenue growth (YoY) | -0.85% | — |
| Net income (latest FY) | $-144.34M | — |
| Operating margin | 0.63% | — |
| Net margin | -3.59% | — |
| 52-week high | $333.30 | $1.87 |
| 52-week low | $146.20 | $0.643 |
| Distance from 52-week high | -12.99% | -47.18% |
| Analyst consensus | buy | — |
| Avg. price target upside | +5.18% | — |
| Average volume | 947.94K | 685.34K |
| Shares outstanding | 48.17M | 103.21M |
| Employees | 18,300 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Charles River Laboratories International is about 137.4 times larger than MaxCyte by market value ($13.97B vs $101.66M).
- CRL has outperformed MXCT by 109.4 percentage points over the past year.
About Charles River Laboratories International
CRL stock →Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 18,300 employees
CRL vs MXCT FAQ
Which is bigger, Charles River Laboratories International or MaxCyte?
Charles River Laboratories International (CRL) is larger, with a market capitalization of $13.97B compared with $101.66M for MaxCyte (MXCT).
Which stock has performed better over the past year, CRL or MXCT?
CRL returned +76.54% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are Charles River Laboratories International and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.